The American Society of Clinical Oncology's algorithm to help oncologists evaluate the clinical benefits, side effects and costs of a cancer drug or therapy will be fine-tuned over the summer and should be available for public comment by the fall, said Dr. Lowell Schnipper, chair of the society's Value in Cancer Care Task Force.
The American Society of Clinical Oncology's algorithm to help oncologists evaluate the clinical benefits, side effects and costs of a cancer drug or therapy will be fine-tuned over the summer and should be available for public comment by the fall, said Dr. Lowell Schnipper, chair of the society's Value in Cancer Care Task Force.
That was one piece of a larger discussion at ASCO's annual meeting about what needs to be done to get soaring cancer care costs under control. Assessing the value of cancer therapies was a major topic, with sessions looking at issues like whether or not patients are getting what they pay for, the ethical obligations faced by physicians and what if anything can be done to help drive down the costs. Although there have been important advances in cancer therapies over the past few decades, drugmakers are more frequently creating “me-too” drugs—generic versions of previous innovations which often sell at higher prices.
Read the full story here: http://bit.ly/1l8yxaE
Source: Modern Healthcare
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Study Finds Obesity May Worsen Multiple Sclerosis: Genetic Analysis Points to Causal Link
November 21st 2024A new study aimed at exploring the relationship between obesity and multiple sclerosis severity using genetic data finds that higher BMI and other obesity measures were associated with increased disability progression in patients with MS.
Read More